Research published in JAMA Nov. 12 suggests that, despite the Organ Procurement and Transplant Network’s overhaul of the U.S. heart allocation system in 2018, CV transplant programs still suffer from variability in survival benefit and a lack of standardized guidelines for ranking candidates.

The net clinical benefit of anticoagulants like warfarin and apixaban slows over time in patients with atrial fibrillation, according to a Circulation: Cardiovascular Quality and Outcomes study, diminishing as people age and face competing risks of death.

The FDA issued a safety communication Nov. 5 reminding the public, healthcare providers and lab workers that the common supplement vitamin B7, or biotin, can interfere with certain diagnostic tests, including troponin tests that can be integral to a heart attack diagnosis.

Women face a greater risk of bleeding and hemorrhagic stroke after PCI than men, according to a new subgroup analysis of the GLOBAL LEADERS trial.

A 61-year-old patient at the West Virginia University Heart and Vascular Institute is the first in the state to receive a successful heart transplant, WVU reported Nov. 10.

A study out of the Smidt Heart Institute at Cedars-Sinai Medical Center suggests e-cigarettes—the culprit behind a vaping epidemic that’s injured more than 2,000 and claimed the lives of at least 39—could be more harmful to CV health than traditional cigarettes.

Nearly three-quarters of atrial fibrillation patients taking dabigatran remain adherent to the medication two years after filling their first prescription, while just over 25% discontinue the drug for various reasons, according to an analysis published in the American Journal of Cardiology.

Results from the world’s largest comprehensive study of hypertrophic cardiomyopathy patients are in—and they’re providing cardiologists with a wealth of previously unknown information about the disease.